NEW YORK — GlaxoSmithKline PLC is reportedly talking this weekend with Human Genome Sciences Inc. about its $2.6 billion offer for the Rockville-based biotech company. British drug maker GlaxoSmithKline made its first bid for the biotech company in April and ...

Tagged with: benlysta bid biotech GlaxoSmithKline PLC Human Genome Sciences Inc. joe biden lupus takeover

WASHINGTON — GlaxoSmithKline LLC will pay $3 billion and plead guilty to promoting two popular drugs for unapproved uses and to failing to disclose important safety information on a third in the largest health care fraud settlement in U.S. history, ...

Tagged with: department of justice drugs glaxosmithkline GlaxoSmithKline PLC

ROCKVILLE — Biotech drugmaker Human Genome Sciences Inc.’s board has adopted a “poison pill” shareholder rights plan to ward off unsolicited takeover bids, and it also has rejected a buyout offer worth nearly $2.6 billion from British pharmaceutical giant GlaxoSmithKline ...

Tagged with: benlysta biotech GlaxoSmithKline PLC human genome sciences lupus poison pill shares stock

LONDON — GlaxoSmithKline PLC has made an offer to take over Rockville-based drug maker Human Genome Sciences Inc. which values the company at nearly $2.6 billion. GlaxoSmithKline, which has profit-sharing agreements with HGS on three drugs but a minimal shareholding, ...

Tagged with: benlysta drugs GlaxoSmithKline PLC human genome sciences lupus Nasdaq price shareholder takeover

WASHINGTON — The Food and Drug Administration on Wednesday approved the first new drug to treat lupus in over 50 years, a milestone that medical experts say could prompt development of other drugs that are even more effective in treating ...

Tagged with: approval drug FDA food and drug administration GlaxoSmithKline PLC lupus maryland rockville